Strategic considerations under the Biologics Price Competition and Innovation Act

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.8, 2013-08, pp. : 915-918

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Generic Drug Regulation in the US Under the Hatch-Waxman Act: A Balance Between Competition and Innovation or Confusion and Intrigue?

By Milne C-P. Cairns C.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 1, 2003-01 ,pp. : 11-27

Adis International

Access to resources Recommend Favorite

The Hatch-Waxman Act: Encouraging Innovation and Generic Drug Competition

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 18, 2010-12 ,pp. : 1950-1959

Bentham Science Publishers

Access to resources Recommend Favorite

The price to pay for pharmaceutical innovation

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 431, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review

By Puig-Junoy Jaume

PharmacoEconomics, Vol. 28, Iss. 8, 2010-08 ,pp. : 649-663

Adis International

Access to resources Recommend Favorite

China encourages price competition between pharma companies

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 284, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite